Cargando…

International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism

OBJECTIVES: This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest. DESIGN: A 19-question international, cross-sectional su...

Descripción completa

Detalles Bibliográficos
Autores principales: Rech, Megan A., Horng, Michelle, Holzhausen, Jenna M., Van Berkel, Megan A., Sokol, Sarah S., Peppard, Sarah, Hammond, Drayton A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314323/
https://www.ncbi.nlm.nih.gov/pubmed/32695997
http://dx.doi.org/10.1097/CCE.0000000000000132
_version_ 1783550043538587648
author Rech, Megan A.
Horng, Michelle
Holzhausen, Jenna M.
Van Berkel, Megan A.
Sokol, Sarah S.
Peppard, Sarah
Hammond, Drayton A.
author_facet Rech, Megan A.
Horng, Michelle
Holzhausen, Jenna M.
Van Berkel, Megan A.
Sokol, Sarah S.
Peppard, Sarah
Hammond, Drayton A.
author_sort Rech, Megan A.
collection PubMed
description OBJECTIVES: This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest. DESIGN: A 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism. SETTING: International survey study. SUBJECTS: Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thrombolytic users were compared with nonusers. Respondents (n = 272) predominately were physicians (62.1%) or pharmacists (30.5%) practicing in an academic medical center (54.8%) or community teaching setting (24.6%). Thrombolytic users (n = 177; 66.8%) were compared with nonusers (n = 88; 33.2%) Thrombolytic users were more likely to work in pulmonary/critical care (80.2% thrombolytic use vs 59.8%; p < 0.01) and emergency medicine (6.8% vs 3.5%; p < 0.01). Users were more likely to have an institutional guideline or policy in place pertaining to the use of thrombolytics in cardiac arrest (27.8% vs 13.6%; p < 0.01) or have a pulmonary embolism response team (38.6% vs 19.3%; p < 0.01). Lack of evidence supporting use and the risk of adverse outcomes were barriers to thrombolytic use. Working in a pulmonary/critical care environment (odds ratio, 2.36; 95% CI, 1.24–4.52) and comfort level (odds ratio, 2.77; 95% CI, 1.7–4.53) were predictive of thrombolytic use in the multivariable analysis. CONCLUSIONS: Most survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally.
format Online
Article
Text
id pubmed-7314323
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73143232020-06-25 International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism Rech, Megan A. Horng, Michelle Holzhausen, Jenna M. Van Berkel, Megan A. Sokol, Sarah S. Peppard, Sarah Hammond, Drayton A. Crit Care Explor Original Clinical Report OBJECTIVES: This survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest. DESIGN: A 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism. SETTING: International survey study. SUBJECTS: Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thrombolytic users were compared with nonusers. Respondents (n = 272) predominately were physicians (62.1%) or pharmacists (30.5%) practicing in an academic medical center (54.8%) or community teaching setting (24.6%). Thrombolytic users (n = 177; 66.8%) were compared with nonusers (n = 88; 33.2%) Thrombolytic users were more likely to work in pulmonary/critical care (80.2% thrombolytic use vs 59.8%; p < 0.01) and emergency medicine (6.8% vs 3.5%; p < 0.01). Users were more likely to have an institutional guideline or policy in place pertaining to the use of thrombolytics in cardiac arrest (27.8% vs 13.6%; p < 0.01) or have a pulmonary embolism response team (38.6% vs 19.3%; p < 0.01). Lack of evidence supporting use and the risk of adverse outcomes were barriers to thrombolytic use. Working in a pulmonary/critical care environment (odds ratio, 2.36; 95% CI, 1.24–4.52) and comfort level (odds ratio, 2.77; 95% CI, 1.7–4.53) were predictive of thrombolytic use in the multivariable analysis. CONCLUSIONS: Most survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally. Wolters Kluwer Health 2020-06-09 /pmc/articles/PMC7314323/ /pubmed/32695997 http://dx.doi.org/10.1097/CCE.0000000000000132 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Clinical Report
Rech, Megan A.
Horng, Michelle
Holzhausen, Jenna M.
Van Berkel, Megan A.
Sokol, Sarah S.
Peppard, Sarah
Hammond, Drayton A.
International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title_full International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title_fullStr International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title_full_unstemmed International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title_short International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism
title_sort international survey of thrombolytic use for treatment of cardiac arrest due to massive pulmonary embolism
topic Original Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314323/
https://www.ncbi.nlm.nih.gov/pubmed/32695997
http://dx.doi.org/10.1097/CCE.0000000000000132
work_keys_str_mv AT rechmegana internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT horngmichelle internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT holzhausenjennam internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT vanberkelmegana internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT sokolsarahs internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT peppardsarah internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism
AT hammonddraytona internationalsurveyofthrombolyticusefortreatmentofcardiacarrestduetomassivepulmonaryembolism